重组人干扰素α2b注射液治疗儿童急性上呼吸道感染的临床效果及药理机制

The clinical effect and pharmacological mechanism of recombinant human interferon α2b in the treatment of acute upper respiratory tract infection in children

目的探究重组人干扰素α2b注射液治疗儿童急性上呼吸道感染的临床效果及药理机制。方法 66例急性上呼吸道感染患者,随机分为治疗组和对照组,各33例。两组患儿均给予常规综合性治疗,治疗组在常规综合性基础上给予重组人干扰素α2b注射液。比较两组治疗效果及临床症状消失时间。结果治疗组治疗总有效率93.9%高于对照组的75.8%,差异有统计学意义(P<0.05)。治疗后,治疗组鼻塞、流涕、喷嚏、咽喉痛、咳嗽的消失时间分别为(3.68±1.23)、(3.73±1.56)、(2.21±1.27)、(6.25±1.57)、(6.59±1.24)d,均短于对照组的(6.42±1.35)、(7.12±1.38)、(4.79±1.13)、(8.25±1.36)、(9.31±1.22)d,差异均有统计学意义(P<0.05)。结论使用重组人干扰素α2b注射液治疗儿童急性上呼吸道感染,临床效果显著,症状改善时间较短,其更加安全可靠,值得广泛推荐。

Objective To investigate the clinical effect and pharmacological mechanism of recombinant human interferon α2b in the treatment of acute upper respiratory tract infection in children. Methods A total of 66 patients with acute upper respiratory tract infection were randomly divided into treatment group and control group, with 33 cases in each group. Both groups were given conventional comprehensive treatment,and the treatment group was given recombinant human interferon α2b injection on the basis of conventional comprehensive treatment. The therapeutic effect and disappearance time of clinical symptoms were compared between the two groups. Results The total effective rate of treatment 93.9% in the treatment group was higher than 75.8% in the control group, and the difference was statistically significant(P<0.05). After treatment, the disappearance times of nasal congestion, runny nose, sneezing, sore throat, and cough in the treatment group were(3.68±1.23),(3.73±1.56),(2.21±1.27),(6.25±1.57), and(6.59±1.24) d, which were shorter than(6.42±1.35),(7.12±1.38),(4.79±1.13),(8.25±1.36), and(9.31±1.22) d of the control group, and the difference was statistically significant(P<0.05). Conclusion Recombinant human interferon α2 b has significant clinical effect on children with acute upper respiratory tract infection, with shorter symptom improvement time. It is safer and more reliable, and it is worthy of wide recommendation.